Table 1. Baseline patient characteristics and treatment follow-up period.
| Apixaban (n = 7,438) | Dabigatran (n = 4,661) | Rivaroxaban (n = 17,801) | Warfarin (n = 15,461) | |||||
|---|---|---|---|---|---|---|---|---|
| N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | |
| Age | 68.5 | 12.4 | 66.5 | 12.4 | 67.1 | 12.3 | 71.7 | 12.1 |
| 18–64 | 3111 | 41.8 | 2234 | 47.9 | 8245 | 46.3 | 4845 | 31.3 |
| 65–74 | 1805 | 24.23 | 1096 | 23.5 | 4208 | 23.6 | 3595 | 23.3 |
| 75+ | 2522 | 33.9 | 1331 | 28.6 | 5348 | 30.0 | 7021 | 45.4 |
| Sex | ||||||||
| Male | 4566 | 61.4 | 3028 | 65.0 | 11310 | 63.5 | 9254 | 59.9 |
| Female | 2872 | 38.6 | 1633 | 35.0 | 6491 | 36.5 | 6207 | 40.2 |
| Embolic or Primary Ischemic Stroke |
523 | 7.0 | 259 | 5.6 | 1056 | 5.9 | 1551 | 10.0 |
| Dyspepsia or Stomach Discomfort | 1082 | 14.6 | 564 | 12.1 | 2548 | 14.3 | 2470 | 16.0 |
| Congestive Heart Failure | 1454 | 19.6 | 873 | 18.7 | 3293 | 18.5 | 4021 | 26.0 |
| Coronary Artery Disease | 2410 | 32.4 | 1283 | 27.5 | 5112 | 28.7 | 5305 | 34.3 |
| Diabetes | 2108 | 28.3 | 1269 | 27.2 | 4802 | 27.0 | 4987 | 32.3 |
| Hypertension | 5585 | 75.1 | 3253 | 69.8 | 12690 | 71.3 | 11334 | 73.3 |
| Renal Disease | 638 | 8.6 | 333 | 7.1 | 1398 | 7.9 | 2242 | 14.5 |
| Myocardial Infarction | 469 | 6.3 | 251 | 5.4 | 1089 | 6.1 | 1378 | 8.9 |
| History of Stroke or TIA | 754 | 10.1 | 413 | 8.9 | 1574 | 8.8 | 2061 | 13.3 |
| History of Bleeding | 1012 | 13.6 | 536 | 11.5 | 2421 | 13.6 | 2800 | 18.1 |
| CHA2DS2-VASc Score* | 2.8 | 1.6 | 2.6 | 1.7 | 2.6 | 1.7 | 3.2 | 1.7 |
| 0 | 514 | 6.9 | 485 | 10.4 | 1650 | 9.3 | 766 | 5.0 |
| 1 | 1222 | 16.4 | 908 | 19.5 | 3401 | 19.1 | 1809 | 11.7 |
| 2 | 1644 | 22.1 | 1027 | 22.0 | 3884 | 21.8 | 2750 | 17.8 |
| ≥3 | 4058 | 54.6 | 2241 | 48.1 | 8866 | 49.8 | 10136 | 65.6 |
| Charlson Comorbidity Index Score | 1.8 | 2.0 | 1.6 | 1.9 | 1.7 | 2.0 | 2.3 | 2.3 |
| 0 | 2244 | 30.2 | 1631 | 35.0 | 6117 | 34.4 | 3741 | 24.2 |
| 1 | 1899 | 25.5 | 1201 | 25.8 | 4468 | 25.1 | 3434 | 22.2 |
| 2 | 1270 | 17.1 | 729 | 15.6 | 2721 | 15.3 | 2499 | 16.2 |
| ≥3 | 2025 | 27.2 | 1100 | 23.6 | 4495 | 25.3 | 5787 | 37.4 |
| Treatment Follow-up (in days) | 148 | 138 | 177 | 178 | 175 | 171 | 164 | 162 |
| Median | 95 | - | 100 | - | 111 | - | 101 | - |
| IQR | 36–215 | - | 30–255 | - | 35–261 | - | 40–233 | - |
SD: Standard Deviation; TIA: Transient Ischemic Attack; IQR: Interquartile Range.
*The CHA2DS2-VASc score was calculated as the sum of points associated with each of the following attributes: congestive heart failure (1 point), hypertension (1 point), age ≥75 (2 points), diabetes (1 point), prior stroke or TIA (2 points), vascular disease (1 point), age 65–74 (1 point), female (1 point).